173 related articles for article (PubMed ID: 15331151)
1. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.
Zetterberg H; Andreasen N; Blennow K
Neurosci Lett; 2004 Sep; 367(2):194-6. PubMed ID: 15331151
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.
Wyss-Coray T; Lin C; Yan F; Yu GQ; Rohde M; McConlogue L; Masliah E; Mucke L
Nat Med; 2001 May; 7(5):612-8. PubMed ID: 11329064
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
[TBL] [Abstract][Full Text] [Related]
5. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease.
Wyss-Coray T; Masliah E; Mallory M; McConlogue L; Johnson-Wood K; Lin C; Mucke L
Nature; 1997 Oct; 389(6651):603-6. PubMed ID: 9335500
[TBL] [Abstract][Full Text] [Related]
6. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
Motter R; Vigo-Pelfrey C; Kholodenko D; Barbour R; Johnson-Wood K; Galasko D; Chang L; Miller B; Clark C; Green R
Ann Neurol; 1995 Oct; 38(4):643-8. PubMed ID: 7574461
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
8. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
9. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
11. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
13. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ; Ganzer S; Müller-Thomsen T
Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta1 is increased in a transgenic mouse model of familial Alzheimer's disease and causes neuronal apoptosis.
Salins P; He Y; Olson K; Glazner G; Kashour T; Amara F
Neurosci Lett; 2008 Jan; 430(1):81-6. PubMed ID: 18063474
[TBL] [Abstract][Full Text] [Related]
15. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients.
Rota E; Bellone G; Rocca P; Bergamasco B; Emanuelli G; Ferrero P
Neurol Sci; 2006 Apr; 27(1):33-9. PubMed ID: 16688597
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
17. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
19. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
20. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
Iqbal K; Flory M; Khatoon S; Soininen H; Pirttila T; Lehtovirta M; Alafuzoff I; Blennow K; Andreasen N; Vanmechelen E; Grundke-Iqbal I
Ann Neurol; 2005 Nov; 58(5):748-57. PubMed ID: 16247771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
